Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space.
Tandem Diabetes’ technology will create a new approval pathway for predictive dosing software that can be used with other devices.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
The San Diego-based company has is in the midst of one of the most precipitous turnarounds in the medical device industry and is well positioned to grow alongside the expanding insulin pump market.
It’s probably not often that the delivery of a new insulin pump prompts a diabetic to upload a YouTube video of her breathlessly unwrapping the box. Over the nearly 8 minute video, she repeatedly gushes over the device and its features. “Oh my gosh, I am so excited,” says Sarah who goes by the username […]
Tandem Diabetes Care Inc., a San Diego, medical device startup that has developed the first touch-screen insulin delivery system, has raised $36.4 million in its quest to garner $50 million.